← Back to Search
Nanosizing--oral Formulation Development And Biopharmaceutical Evaluation.
F. Kesisoglou, S. Panmai, Y. Wu
Published 2007 · Medicine, Biology
Download PDFAnalyze on Scholarcy
Poor aqueous solubility represents a major hurdle in achieving adequate oral bioavailability for a large percentage of drug compounds in drug development nowadays. Nanosizing refers to the reduction of the active pharmaceutical ingredient (API) particle size down to the sub-micron range, with the final particle size typically being 100-200 nm. The reduction of particle size leads to a significant increase in the dissolution rate of the API, which in turn can lead to substantial increases in bioavailability. This review describes the principles behind nanosizing, the production and characterization of nanoformulations as well as the current experience with utilization of such formulations in vivo.
This paper references
Nanosuspension Formulations for Low-Soluble Drugs: Pharmacokinetic Evaluation Using Spironolactone as Model Compound
P. Langguth (2005)
Influence of physicochemical properties and intestinal region on the absorption of 3-fluoro-2-pyrimidylmethyl 3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide, a water insoluble thrombin inhibitor, in dogs.
D. Euler (2004)
Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs.
Jun-ichi Jinno (2006)
Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems.
C. Pouton (2000)
Single dose and multiple dose studies of itraconazole nanoparticles.
J. M. Vaughn (2006)
Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle.
L. Jia (2003)
Nanosuspensions in drug delivery
Barrett E. Rabinow (2004)
Reaktionsgeschwindigkeit in heterogenen Systemen
E. Brunner (1904)
Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique
R. Mueller (1998)
Pharmacokinetics of Itraconazole and Hydroxyitraconazole in Healthy Subjects after Single and Multiple Doses of a Novel Formulation
J. Mouton (2006)
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection.
K. Peters (2000)
The rate of solution of solid substances in their own solutions
A. A. Noyes (1897)
Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base.
J. Hecq (2006)
Formulation of amphotericin B as nanosuspension for oral administration.
O. Kayser (2003)
Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen
W. Nernst (1904)
The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
Y. Wu (2004)
Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption.
L. X. Yu (1996)
The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs
M. Mosharraf (1995)
Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers
Anup K. Majumdar (2006)
Particle Size Measurement
T. Allen (1965)
Nanosuspensions: a promising drug delivery strategy
V. Patravale (2004)
Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs.
P. Kocbek (2006)
Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation.
C. Keck (2006)
Nanosizing: a formulation approach for poorly-water-soluble compounds.
E. Merisko-Liversidge (2003)
Freeze-drying of nanoparticles: formulation, process and storage considerations.
W. Abdelwahed (2006)
Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages.
O. Kayser (2000)
Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans.
C. Y. Lui (1986)
Improving cyclodextrin complexation of a new antihepatitis drug with glacial acetic acid
J. L. H. Johnson (2008)
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs.
R. N. Gursoy (2004)
Current strategies for engineering drug nanoparticles
A. Date (2004)
Foundations of Colloid Science
R. Hunter (1987)
Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis
N. Schöler (2001)
Poor aqueous solubility-an industry wide problem in drug discovery
C. Lipinski (2002)
Nanomilling in stirred media mills
F. Stenger (2005)
Effect of Nanonization on Absorption of 301029: Ex Vivo and In Vivo Pharmacokinetic Correlations Determined by Liquid Chromatography/Mass Spectrometry
L. Jia (2004)
Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems.
Jiahui Hu (2003)
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
Supersaturation Produces High Bioavailability of Amorphous Danazol Particles Formed by Evaporative Precipitation into Aqueous Solution and Spray Freezing into Liquid Technologies
J. M. Vaughn (2006)
Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.
R. Mueller (2001)
This paper is referenced by
Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution.
N. El-gendy (2009)
New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery.
A. Sosnik (2010)
Comparative In vivo Evaluation of Aripiprazole Coprecipitate, Nanoparticles and Marketed Tablets in Healthy Human Volunteers and In vitro-In vivo Correlation
A. Abdelbary (2011)
Production de particules presque monodispersées à l'aide d'un broyage et d'une séparation à membrane.
José Luis Santos (2013)
A REVIEW ON DRIED NANOSUSPENSIONS- A NOVEL FORMULATION TO ENHANCE SOLUBILITY OF POORLY AQUEOUS SOLUBLE DRUGS
Sureddi V. Lakshmi (2014)
Amino functionalized chiral mesoporous silica nanoparticles for improved loading and release of poorly water-soluble drug
X. Wang (2019)
Development of nanofibrous membranes for enzymatic food processing
M. Mason (2017)
NANOSUSPENSIONS: A STRATEGY FOR IMPROVED BIOAVAILABILITY
S. Pattnaik (2013)
Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol.
Xiaoqing Miao (2011)
Nanodispersions Platform for Solubility Improvement
Ezeddin Kolaib (2013)
Investigating the Effect of Mixed Surfactants with Different HLBs on the Properties of Solid Lipid Nanoparticle of Spironolactone
Zhila Imani (2018)
Nanosuspension: A Potential Nanoformulation for Improved Delivery of Poorly Bioavailable Drug
M. A. Rahman (2013)
Influence of Formulation Parameters on Redispersibility of Naproxen Nanoparticles from Granules Produced in a Fluidized Bed Process
Martin Wewers (2020)
Domperidone nanocrystals with boosted oral bioavailability: fabrication, evaluation and molecular insight into the polymer-domperidone nanocrystal interaction
Stalielson Tatenda Ndlovu (2018)
Toxicology studies of primycin-sulphate using a three-dimensional (3D) in vitro human liver aggregate model.
Ágota Pénzes (2017)
Evaluation of the antidiarrheal activity of the leaf extract of Parquetina nigrescens and formulation into oral suspensions
A. Kola-Mustapha (2019)
Effect of polymer species and concentration on the production of mefenamic acid nanoparticles by media milling.
Atsutoshi Ito (2016)
Ultrafine clarithromycin nanoparticles via anti-solvent precipitation in subcritical water: Effect of operating parameters
Yuan Pu (2017)
Study on formability of solid nanosuspensions during nanodispersion and solidification: I. Novel role of stabilizer/drug property.
P. Yue (2013)
A mini review of nanosuspensions development
Y. Liu (2012)
Drug permeation across intestinal epithelial cells using porous silicon nanoparticles.
Luis M Bimbo (2011)
Stabilizers used in nanocrystal based drug delivery systems
G. Shete (2014)
Hyo Na Kim (2015)
Novel nanosuspension‐based dissolving microneedle arrays for transdermal delivery of a hydrophobic drug
Lalit Vora (2018)
Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique.
Qing-Ri Cao (2012)
A new and improved method for the preparation of drug nanosuspension formulations using acoustic mixing technology.
Dennis H Leung (2014)
Impact of process parameters on the breakage kinetics of poorly water-soluble drugs during wet stirred media milling: a microhydrodynamic view.
A. Afolabi (2014)
Non-invasive strategies for targeting the posterior segment of eye.
Asadullah Madni (2017)
Investigation of the Particle Growth of Fenofibrate following Antisolvent Precipitation and Freeze–Drying
Teresa B. Tierney (2015)
Current oscillations generated by precipitate formation in the mixing zone between two solutions inside a nanopore.
Erik C. Yusko (2010)
Stepwise Use of Additives for Improved Control over Formation and Stability of Mefenamic Acid Nanocrystals Produced by Antisolvent Precipitation
Katalin Bodnár (2017)
Amino functionalized mesoporous silica with twisted rod-like shapes: Synthetic design, in vitro and in vivo evaluation for ibuprofen delivery
Yumei Wang (2020)See more